8-K
filed November 4, 2025, 6:59 PM ET
ticker SLE
CIK 0001621672
regulatory
confidence high
sentiment positive
materiality 0.70
Super League regains Nasdaq compliance; delisting hearing cancelled
Super League Enterprise, Inc.
- Nasdaq notified Super League on Oct 28, 2025 of regained compliance with Rule 5550(b).
- Company now in compliance with all continued listing requirements.
- Scheduled November 11, 2025 hearing before Hearings Panel has been cancelled.
- SLE common shares continue to trade uninterrupted on Nasdaq.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001437749-25-033047
- form_type
- 8-K
- ticker
- SLE
- cik
- 0001621672
- company_name
- Super League Enterprise, Inc.
- filed_at
- 2025-11-04T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:39.949278+00:00
- generated_at
- 2026-05-17T00:38:16.328559+00:00
- sec_items
- ["8.01", "9.01"]
- event_type
- regulatory
- sentiment
- positive
- materiality_score
- 0.7
- calibrated_materiality_score
- 0.7
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001437749-25-033047
- json_url
- https://secwatch.observer/filing/0001437749-25-033047.json
- markdown_url
- https://secwatch.observer/filing/0001437749-25-033047.md
- text_url
- https://secwatch.observer/filing/0001437749-25-033047.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1621672/000143774925033047/0001437749-25-033047-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1621672/000143774925033047/slgg20251104_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
SLXN
Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted
Silexion Therapeutics Corp
May 29, 2026, 7:00 AM ET
regulatory
Items 3.03, 5.03, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
RR
Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing
RICHTECH ROBOTICS INC.
May 28, 2026, 4:49 PM ET
regulatory
Items 3.01, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
JAGX
Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027
Jaguar Health, Inc.
May 27, 2026, 9:10 AM ET
regulatory
Items 7.01, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
MBOT
Microbot Medical receives Israeli regulatory approval for LIBERTY System, first outside U.S.
Microbot Medical Inc.
May 26, 2026, 8:30 AM ET
regulatory
Items 7.01, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
LRHC
La Rosa Holdings receives Nasdaq deficiency notice for late 10-K and 10-Q filings
La Rosa Holdings Corp.
May 22, 2026, 5:20 PM ET
regulatory
Items 3.01, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
AVXL
Anavex receives Nasdaq delinquency notice for late 10-Q filing; deadline July 20, 2026
ANAVEX LIFE SCIENCES CORP.
May 22, 2026, 8:15 AM ET
regulatory
Items 3.01, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
ADGM
Adagio submits PMA to FDA for vCLAS VT ablation system; trial shows 97.4% acute success
Adagio Medical Holdings, Inc.
May 21, 2026, 4:31 PM ET
regulatory
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
CGTX
Cognition Therapeutics completes productive FDA meeting for zervimesine in DLB psychosis
COGNITION THERAPEUTICS INC
May 21, 2026, 7:34 AM ET
regulatory
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: regulatory
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.